Biogenicskorea Co., Ltd.

Company Profile

Biogenicskorea is the nation's first postbiotics company holding lactobacillus plantarum nF1 strain which is developed kimchi-derived vegetable lactobacillus. We have Korean, US and numuorus patents for technology and efficacy of nF1 strain. We are a manufacturer and distributor of various product divisions as using the strain. We currently supplies heat-treated lactobacillus nF1 to F&B compnay and pharmaceuticals like Chongkeundang healthcare, Seoulmilk and Handok. We launched next-generation lactobacillus postbiotics series, our own brand "GraBio".

Company History

January, 2020 Launched lactobacillus postbiotics series, GraBio postbiotics
January, 2018 Commenced supply of nF1 for Seoul Milk Selling nF1 contained HMR(Home Meal Replacement) on Seven Eleven, GS25 Business consultation with Gwangdong Pharma, Crown, SoonsooBon etc
January, 2017 Commenced supply of raw ingredient nF1 for Purmil(N-1), Namyang Dairy Product(Bulgaris lactobacillus Water, Yoguri Mong) Registered a technical patent on Nano-Sized lactobacillus in the United States Acquired the certification labeling required to export to China (nF1, Kimchi lactobacillus series, lactobacillus drinks) Corporate R&D Center recognized
January, 2016 Developed health functional beverage designed to enhance immunity and to improve intestinal health, nano-type kimchi lactobacillus composite, health functional food and confectionery and registered relevant patents accordingly Acquired ISO9001: 2008 Certification Made commercial launch of "Kimchi lactobacillus 5000" and "Organic Maqui Berry"
January, 2015 Registered a technical patent on “Lactobacillus with the capacity of producing and inducing IL-12 and its manufacturing method thereof” Launched 『Kimchi lactobacillus 2000』
January, 2014 Selected for 2014 Foond Functionality Evaluation Support Project (Ministry of Agriculture, Food and Rural Affairs)
January, 2013 Established Biogenics Korea Co., Ltd. Patent application for “Nano-type kimchi lactobacillus“ pending Patent application for “Lactobacillus with the capacity of producing and inducing IL-12 and its manufacturing method thereof” pending Launched 『Kimchi lactobacillus 1000』 『Kimchi lactobacillus 3000』
January, 2012 “Prevention of colitis of nF1 using a mouse and colorectal environment improvement activity test” (National Center of Efficacy Evaluation for the Development of Health Products Targeting Digestive Disorders, NCEED)
January, 2011 Doctor of Agriculture Gan Tatsuhiko’s thesis “The era of Biogenics-the beginning of clarifying the true mechanism of lactobacillus “
January, 2008 Successfully developed kimchi-derived vegetable lactobacillus : World’s first nanonized lactobacillus(nF1) Established Biogenics Liaison Council (Japan) Doctor of Agriculture Gan Tatsuhiko’s thesis “Longevity immunity and lactobacillus: The efficacy of nanonized lactobacillus that induces Th1 cell“
June, 2007 Successfully developed the technology that cultivates kimchi-derived vegetable lactobacillus into ultrafine Lactobacillus Plantarum and named it nF1

Factory / Branch Office

Biogenicskorea Co., Ltd. (www.biogenicskorea.com)

  • The person in charge

    Jae Won Kim
  • Telephone

    82-7048141749
  • Fax

    82-25616053
  • Address

    315 Gangnam-daero, Seocho-gu, Seoul (06628)
Business Type Manufacturer
Main Product VitaC300, Gentinol200 New, EGCG200
Established 2011-02-09
Total Annual Revenue 5~6 billion (KRW)
Total Employees 11~50 people